Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Date:10/30/2008

involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Eric Rosenberg

Cell: +972-54-566-7713

Office: +972-2-566-0001

Email: eric@oramed.com

Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-467-6950

Office: +972-2-589-2003

Email: matthew@oramed.com


'/>"/>
SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
4. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
6. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
7. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
8. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
9. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
10. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
11. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... MENLO PARK, Calif. , May 26, 2015 /PRNewswire/ ... focused on the emerging field of regenerative medicine, today ... issued in June 2014 were exercised prior to their ... to the Company of $11.7 million. "We ... Pedro Lichtinger , President and CEO of Asterias. "This ...
(Date:5/26/2015)... NORTH CHICAGO, Ill. , May 26, 2015 ... biopharmaceutical company, announced today that it has completed ... and commercial presence in oncology. Pharmacyclics is a ... (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ... "The companies, shared expertise, combined with AbbVie,s broad ...
(Date:5/26/2015)... Just the characterization of being a ... need does not guarantee immediate acceptance. In particular, ... many prior failures is often met with significant skepticism. ... an irony that is often an unappreciated aspect of ... Asymmetrex has found that building acceptance of ...
(Date:5/25/2015)... May 25, 2015 The 2015 ... Industry is a professional and in-depth study on ... Chloride Market with a focus on the ... chloride market research are Linde Industrial Gas, Basf, ... Chemical, Shandong Xinlong Group, Longsheng Group, Juhua Group, ...
Breaking Biology Technology:Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3AbbVie Completes Acquisition of Pharmacyclics 2AbbVie Completes Acquisition of Pharmacyclics 3AbbVie Completes Acquisition of Pharmacyclics 4AbbVie Completes Acquisition of Pharmacyclics 5AbbVie Completes Acquisition of Pharmacyclics 6In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3
... 2008 Plethora Solutions Holdings PLC,("Plethora", AIM: PLE), ... management of urological disorders, today announced that it,has ... Paul Capital,Healthcare. Through this agreement, Plethora will receive ... payable upon signature and a further $10 million,upon ...
... 1, 2008 Cardiac Science,(Nasdaq: CSCX ... diagnosis,resuscitation, rehabilitation, and informatics products, announced today,that ... begin establishing Heartcentrix(R) ECG,connectivity with the Misys ... Healthcare., (Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO ), ...
... has demonstrated that hydrogen can be efficiently stored in ... used in mobile applications. Bald discovered that 30 nanometre ... favourable extraction and storage of hydrogen possible. , ... transport medium for energy. Therefore many future scenarios are ...
Cached Biology Technology:Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 2Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 3Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment 4Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems 2Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems 3
(Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... in how genes, the basic building blocks of the human body, ... post-mortem adult human brain and spinal cord samples from over 100 ... study the expression of every gene in 12 brain regions. The ... They found that the way that the genes are expressed in ...
... BUFFALO, N.Y. Obesity may alter the way we taste ... react to different foods. In a Nov. 13 study ... biologists report that being severely overweight impaired the ability of ... plump mice had fewer taste cells that responded to sweet ...
... There is good evidence from studies of families and ... development of alcoholism. However, hundreds of genes likely are ... only a very small effect. Thus, identifying individual risk ... combines genome-wide association studies (GWAS) with information about which ...
Cached Biology News:Does obesity reshape our sense of taste? 2Study finds gene network associated with alcohol dependence 2
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
...
...
... Pale yellow solid. An N-nitroso-containing diabetogenic ... oxide donor in pancreatic islets. An ... DNA alkylation and DNA strand breaks ... by HPLC. Soluble in H 2 ...
Biology Products: